Patent landscape of novel technologies for combating category-A Arenavirus infections

References

• Kunz S, Moraz M-L. Pathogenesis of arenavirus hemorrhagic fevers. Expert Rev Anti Infect Ther. 2011;9(1):49–59.
   PubMed Web of Science ®Google Scholar
• Hayden FG, Friede M, Bausch DG. Experimental therapies for ebola virus disease: what have we learned ? J Infect Dis. 2017;215:167–170.
   PubMed Web of Science ®Google Scholar
• Kilgore PE, Peters CJ, Mills JN, et al. Prospects for the control of bolivian hemorrhagic fever. Emerg Infect Dis. 1995;1(3):97–100. .
   PubMed Web of Science ®Google Scholar
• Payne S. Family Arenaviridae. Viruses. 2017;215–218. Academic Press.DOI: 10.1016/B978-0-12-803109-4.00025-8
   Google Scholar
• Lassa Fever. CDC, USA 2014. p. 1–3.
   Google Scholar
• Singh VK, Garcia M, Wise SY, et al. Medical countermeasures for unwanted CBRN exposures: part I chemical and biological threats with review of recent countermeasure patents. Expert Opin Ther Pat. 26(12): 1431–1447. 2017. .
   Web of Science ®Google Scholar
• Jay MT, Glaser C, Charles FF, Zoonosis Update The arenaviruses. JAVMA. 2005;227(6):904–915. .
   PubMed Web of Science ®Google Scholar
• Lee AM, Rojek JM, Spiropoulou CF, et al. Unique small molecule entry inhibitors of hemorrhagic fever arenaviruses. J Biol Chem. 2008;283(27):18734–18742. .
   PubMed Web of Science ®Google Scholar
• Kieny DMP. Guidance for managing ethical issues in infectious disease outbreaks. 2016. p. 1–68. ISBN : 9789241549837.
   Google Scholar
• Parsy M-L, Harlos K, Huiskonen JT, et al. Crystal structure of venezuelan hemorrhagic fever virus fusion glycoprotein reveals a class 1 postfusion architecture with extensive glycosylation. J Virol. 2013;87(23):13070–13075. .
   PubMed Web of Science ®Google Scholar
• Tang-Huau TL, Feldmann H, Rosenke K, Animal models for Lassa virus infection. Curr Opin Virol. 2019;37:112–117. .
   PubMed Web of Science ®Google Scholar
• Manzione ND, Salas RA, Paredes H, et al. Venezuelan hemorrhagic fever: clinical and epidemiological studies of 165 cases. Clinl Infect Dis. 1998;26(2):308–313. .
   PubMed Web of Science ®Google Scholar
• Salazar-Bravo J, Ruedas LA, Yatesi, TL. Mammalian reservoirs of Arenaviruses. Berlin Heidelberg: Springer-Verlag; 2002. ( Arenaviruses I).
   Google Scholar
• Racsa LD, Kraft CS, Olinger GG, et al. Viral Hemorrhagic Fever Diagnostics. Clinl Infect Dis. 2016;62(2):214–219. .
   PubMed Web of Science ®Google Scholar
• Vela E, Animal models, prophylaxis, and therapeutics for arenavirus infections. Viruses. 2012;4(9):1802–1829. .
   PubMed Web of Science ®Google Scholar
• Gaudinski MR, Coates EE, Novik L, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. Lancet. 2019;393:889–898.
   PubMed Web of Science ®Google Scholar
• Postnikova EN, Pettitt J, Ryn CJV, et al. Scalable, semi-automated fluorescence reduction neutralization assay for qualitative assessment of Ebola virus-neutralizing antibodies in human clinical samples. PLoS One. 2019;14(8):1–13. .
   Web of Science ®Google Scholar
• Sivapalasingam S, Kamal M, Slim R, et al. Safety, pharmacokinetics, and immunogenicity of a co-formulated cocktail of three human monoclonal antibodies targeting Ebola virus glycoprotein in healthy adults: a randomised, first-in-human phase 1 study. Lancet Infect Dis. 2018;18(8):1–10.
   PubMed Web of Science ®Google Scholar
• Radhakrishnan I, Sreerupa C, Shenghua Z, Inventors; Sperovie Biosciences Inc(US), assignee. Nanoparticle Formulations of STING Agonists. WO2019161171A1. 2019 Aug 22.
   Google Scholar
• Shanta B, Kp L, By S, inventors; Biocryst Pharma Inc, assignee. Methods and compositions for inhibition of polymerase US10022375B2. 2018 Jul 17.
   Google Scholar
• Wei W, Gengfu X, Yang L, et al., inventors; Wuhan Inst Virology CAS, assignee. Application of bergamottin and/or casticin and product applying same CN109864988A. 2019 Jun 11.
   Google Scholar
• Nathanael G, Priscilla Y, Qingsong L, et al., inventors; Dana Farber Cancer Institutee Inc, President fellows of harvard college, assignee. Host targeted inhibitors of dengue virus and other viruses US9879003B2. 2018 Jan 30.
   Google Scholar
• Stephanie HC, Umetsu JT, Kruyff RHD, et al., inventors; Children s Medical Center Corp, Dana Farber Cancer Institute Inc, assignee. Compositions and methods for inhibiting viral entry US20150297677A1. 2012 Dec 13.
   Google Scholar
• Petit R, Perry K, Michael F, et al. Principota inventors; Advaxis, Inc. assignee. Immunotherapy based on personalized delivery vectors and their use JP2018515588. 2016.
   Google Scholar
• Xiaoyan P, Yan W, Gengfu X, inventors; Wuhan Inst Virology CAS, assignee. Neutralizing antibody against Junin virus, preparation method thereof and application thereof CN110204613A. 2019 Sep 06.
   Google Scholar
• Ternovoi VA, Shikov AN, Sementsova AO, et al., inventors; Federal State Institution of Science “State Scientific Center for Virology and Biotechnology” Vector ““ (FBSI SSC WB “Vector”), assignee. Set of oligonucleotide primers and fluorescently labelled probe for species-specific express-identification of rna of junin virus by method of polymerase chain reaction in real time RU252938C1. 2014 Aug 20.
   Google Scholar
• Patterson M, Grant A, Paessler S. Epidemiology and pathogenesis of bolivian hemorrhagic fever. Curr Opin Virol. 2014;5:82–90.
   PubMed Web of Science ®Google Scholar
• Shenwei L, Zhengan T, Qi C, et al., inventors; Shanghai Entry Exit Inspection Quarantine Bureau Of People S Republic Of China, assignee. A kind of indirect immunofluorescene assay method of Machupo virus IgG antibody CN105929170. 2018 Mar 09.
   Google Scholar
• Dongcheng D, Bjras M, Hd E, inventors; Kineta Viral Hemorrhagic Fever LLC, assignee. Antiviral drugs for treatment of arenavirus infection US9498470B2. 2016 Nov 22.
   Google Scholar
• Smith DR, Holbrook MR. Gowen BB Animal models of viral hemorrhagic fever. Antiviral Res. 2014;112:59–79.
   PubMed Web of Science ®Google Scholar
• Feng Z, Gj S, Ao O, et al., inventors; Broad Inst Inc,Harvard College,Massachusetts Institute Of Technology, assignee. Crispr system based antiviral therapy WO2019010422A1. 2019 Jan 10.
   Google Scholar
• Iversen Patrick I, Mourich Dan V, Schnell Frederick J, et al., Inventors; Sarepta Therapeutics Inc, assignee. Antisense modulation of interleukins 17 and 23 signaling US9238042B2. 2016 Jan 19.
   Google Scholar
• Golden JE, Chung D, inventors; University of Kansas University of Louisville Research Foundation (ULRF), assignee. Inhibitors of viruses US20180086749A1. 2015 May 11.
   Google Scholar
• Rudolf R, inventor; Diagen Gmbh(SI), assignee. New stable pentadecapeptide salts, a process for preparation thereof, a use thereof in the manufacture of pharmaceutical preparations and a use thereof in therapy EP2968442B1. 2017 Sep 13.
   Google Scholar
• Dltj C, Luis M, Masaharu I, inventors; Univ Rochester, assignee. Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) US9943585B2. 2018 Apr 17.
   Google Scholar
• Bingde Z, Jihua Z, Fuyong L, et al., inventors; Ningbo Medical System Biotechnology Co Ltd, assignee. A kind of gene recombinant human C peptide fusion protein and the preparation method and application thereof CN105601750B. 2019 May 31.
   Google Scholar
• Vhm G, Mette E, inventors; La Jolla Institutee For Allergy Immunology Cal, assignee. Methods of treating viral infection with IL-10 receptor antagonists US7553932B1. 2009 Jun 30.
   Google Scholar
• Branco Luis M, Garry Robert F, Geisbert Thomas W et al., inventors; Scripps Research Inst,Administrators Of Tulane Educational Fund,Univ Texas,Zalgen Lab Llc, assignee. Arenavirus monoclonal antibodies and uses WO2018106712A1. 2018 Jun 14.
   Google Scholar
• Tomaskova J, Kopacek J, Pastorek J, et al., inventors; Bioscience Slovakia, assignee. Viral diagnostics US8883429B2. 2011 Jan 07.
   Google Scholar
• Shuping T, Cui L, Gang W, et al., inventors; Staidson Beijing Bio Pharma S Coltd, assignee. Primer, probe and method for detecting mouse lymphocyte choriomeningitis virus CN102399904B. 2014 Jun 04.
   Google Scholar
• Freedman B, Harty R, Reitz AB, et al., inventors; University of Pennsylvania, assignee. Novel effective antiviral compounds and methods using same US20170114060A1. 2014 Jun 03.
   Google Scholar
• Steven B, inventor; Baranowitz Steven(US), assignee. Prevention and treatment of viral infections US10383852B2. 2019 Aug 20.
   Google Scholar
• Wei W, Peilin W, Shaobo W, et al., inventors; Wuhan Inst Virology CAS assignee. Application of the lacidipine in the drug of preparation treatment arenavirus infection CN106511343B. 2018 Dec 11.
   Google Scholar
• Bolken Tove C, Dai Dongchen G, Hruby Dennis E, et al., inventors; Kineta Four Llc, assignee. Antiviral drugs for treatment of arenavirus infection US9199920B2. 2015 Dec 01.
   Google Scholar
• Zhuang X, McKeating JA, inventors; University of Birmingham, assignee. Treatment and prevention of viral infection US20190203211A1. 2016 Sep 05.
   Google Scholar
• Marjorie R, Susan D, Vandana S, et al., inventors; Arbutus Biopharma Corp,US Army, assignee. Compositions and methods for silencing genes involved in hemorrhagic fever US8455455B1. 2013 Jun 04.
   Google Scholar
• Garry Robert F, Spence Jennifer S, inventors; Administrators Of Tulane Educational Fund, assignee. Arenavirus inhibiting peptides and uses therefor US8999925B2. 2015 Apr 07.
   Google Scholar
• Roger H, Stuart D, Emma K, inventors; Sec Dep For Health Social Care(Gb), assignee. Lassa virus antigenic composition WO2019145739A1. 2019 Aug 01.
   Google Scholar
• Luis M, Dltj C, inventors; Scripps Research Institutee California,Univ Rochester,Scripps Research Inst, assignee. Arenavirus vaccine US10342861B2. 2019 Jul 09.
   Google Scholar
• Guirakhoo F, Domi A, inventors; Geovax Inc., assignee. Compositions and methods for generating an immune response to lasv WO2019/018501A1. 2017 Jul 18.
   Google Scholar
• Connie S, Kate B, Niranjan S, et al., inventors; Inovio Pharma Inc, assignee. DNA vaccine against lassa virus EP2731628B1. 2019 Sep 04.
   Google Scholar
• Jasny E, Petsch B, inventors; Curevac Ag, assignee. Lassa virus vaccine WO2018/115525A1. 2016 Dec 23.
   Google Scholar
• Xuexing Z, Xuejie Y, Fuzhong X, et al., inventors; Shandong Univ, assignee. Lassa fever virus-like particles as well as preparation method and application thereof CN105296507A. 2016 Feb 03.
   Google Scholar
• Francis G, Manuel B, Alan B, et al., inventors; Autoimmune Technology Llc,Administrators Of Tulane Educational Fund,Autoimmune Tech Llc, assignee. Immunoprotective primary mesenchymal stem cells and methods US10357562B2. 2019 Jul 23.
   Google Scholar
• Zhengan T, Shenwei L, Qi C, et al. inventors; shanghai entry exit inspection quarantine bureau of peoples republic of china, assignee. A Kind Of Indirect Immunofluorescene Assay Method Of Lassa Virus Igg Antibody. 09-Feb-2018;CN105548539B:.
   Google Scholar
• Feng C, Hailei W, Qinggui Y, et al., inventors; Nantong Int Travel Health Care Clinic, assignee. Quick fluorescent PCR detection kit of lassa virus and primer probe combination of detection kit CN109338016A. 2019 Feb 15.
   Google Scholar
• Zhai L, Jing Y, Liping M, et al., inventors; Inst Disease Control Prevention Pla,Wuhan Inst Virology Cas, assignee. Lassa fever virus detection kit and special primer thereof CN109055617A. 2018 Dec 21.
   Google Scholar
• Cmon H, Yang F, Robert J, et al., inventors; Gilead Science Inc, assignee. Methods for treating arenaviridae and coronaviridae virus infections US10251904B2. 2019 Apr 09.
   Google Scholar
• [cited 2019 Sep 1]. https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3161615
   Google Scholar
• Bluemling Gregory R, Painter George R, Perryman David, inventors; Emory University, assignee.4ʹ-Halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto WO2019173602A1. 2019 Sep 12.
   Google Scholar
• Dongcheng D, Hd E, Bt C, et al., inventors; Kineta Four Llc(US), assignee. Antiviral drugs for treatment of Arenavirus infection US9096597B2. 2015 Aug 04.
   Google Scholar
• Ying G, Xiaoyu Z, Tange, et al., inventors; Inst Of Materia Medica Chinese Academy Of Medical Science, assignee. Isavuconazole and application thereof to preparation of medicine for resisting to arenavirus infection CN109745319A. 2019 May 14.
   Google Scholar
• Matthew L, Everett MK, WS E, inventors; Albert Einstein College of Medicine, assignee. Transferrin receptor aptamers and aptamer-targeted delivery US9439973B2. 2016 Sep 13.
   Google Scholar
• Charrel RN, Lamballerie XD. Arenaviruses other than Lassa virus. Antiviral Res. 2003;57(1–2):89–100.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Farrar JJ, NvV C, et al. Dengue. N Engl J Med. 2012;366(15):1423–1432.
   PubMed Web of Science ®Google Scholar